Enanta Pharmaceuticals Inc Asset Resilience Ratio
Enanta Pharmaceuticals Inc asset resilience ratio. Enanta Pharmaceuticals Inc (ENTA) has an Asset Resilience Ratio of 52.58% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Enanta Pharmaceuticals Inc (ENTA) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Enanta Pharmaceuticals Inc (2011–2025)
Asset resilience ratio of Enanta Pharmaceuticals Inc from 2011 to 2025. This chart shows how Enanta Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read Enanta Pharmaceuticals Inc (ENTA) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Enanta Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ENTA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $156.09 Million | 52.58% |
| Total Liquid Assets | $156.09 Million | 52.58% |
Asset Resilience Insights
- Very High Liquidity: Enanta Pharmaceuticals Inc maintains exceptional liquid asset reserves at 52.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Enanta Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Enanta Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Enanta Pharmaceuticals Inc Asset Resilience Ratio by Year (2011–2025)
Enanta Pharmaceuticals Inc asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Enanta Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 55.77% | $156.57 Million | $280.73 Million | -0.24pp |
| 2024-09-30 | 56.01% | $210.95 Million | $376.65 Million | -5.54pp |
| 2023-09-30 | 61.55% | $284.52 Million | $462.27 Million | +7.62pp |
| 2022-09-30 | 53.93% | $205.24 Million | $380.59 Million | +11.56pp |
| 2021-09-30 | 42.37% | $186.80 Million | $440.86 Million | -18.66pp |
| 2020-09-30 | 61.03% | $299.52 Million | $490.79 Million | +3.05pp |
| 2019-09-30 | 57.98% | $284.01 Million | $489.83 Million | -1.12pp |
| 2018-09-30 | 59.10% | $244.83 Million | $414.23 Million | +10.73pp |
| 2017-09-30 | 48.37% | $157.99 Million | $326.64 Million | -20.43pp |
| 2016-09-30 | 68.80% | $193.51 Million | $281.28 Million | +18.60pp |
| 2015-09-30 | 50.19% | $123.48 Million | $246.01 Million | +11.54pp |
| 2014-09-30 | 38.65% | $60.06 Million | $155.41 Million | -40.53pp |
| 2013-09-30 | 79.18% | $92.62 Million | $116.97 Million | +15.44pp |
| 2012-09-30 | 63.75% | $33.25 Million | $52.16 Million | +0.55pp |
| 2011-09-30 | 63.20% | $16.49 Million | $26.10 Million | -- |
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more